ClinicalTrials.gov에 등록된 정보를 기준으로 코로나-19(COVID-19) 관련 글로벌 임상시험 현황을 제공합니다.
전체 2308건의 자료가 검색되었습니다.
| No. | Status | Study Title | Conditions | Interventions | Phase | Sponsor/Collaborators | Funder Type | Number Enrolled | Sex | Age | Locations |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2168 | Not yet recruiting | A Study of Jaktinib Hydrochloride Tablets in the Treatment of Severe Novel Coronavirus Pneumonia | Novel COVID-19-Infected Pneumonia | Drug: Jaktinib hydrochloride tablets Drug: placebo |
Phase 2 | Suzhou Zelgen Biopharmaceuticals Co.,Ltd | INDUSTRY | 60 | All | 18 Years | Changsha Taihe Hospital, Changsha, Hunan, China |
| 2167 | Completed | A Study of LAM-002A for the Prevention of Progression of COVID-19 | COVID-19 Disease | Drug: Apilimod Dimesylate Capsule Other: Placebo |
Phase 2 | OrphAI Therapeutics, Yale University | INDUSTRY | 142 | All | 18 Years | Yale University, New Haven, Connecticut, United States |
| 2166 | Completed | A Study of Liposomal Trans Crocetin, LEAF-4L6715, in Patients With Acute Respiratory Distress Syndrome Due to COVID-19, Sepsis or Other Causes | Acute Respiratory Distress Syndrome | Drug: LEAF-4L6715 | Phase 2 | Institut de cancerologie Strasbourg Europe, LEAF4Life, Inc. | OTHER | 37 | All | 18 Years | Hopitaux Universitaires de Strasbourg, Strasbourg, France Institut de cancerologie Strasbourg Europe, Strasbourg, France |
| 2165 | Terminated | A Study of LY3127804 in Participants With COVID-19 | Pneumonia | Drug: LY3127804 Drug: Placebo |
Phase 2 | Eli Lilly and Company | INDUSTRY | 95 | All | 18 Years | Banner Univ Med Ctr Phoenix, Phoenix, Arizona, United States Banner Univ Med Ctr Tucson, Tucson, Arizona, United States National Jewish Medical and Research Center, Denver, Colorado, United States Nuvance Danbury Hospital, Danbury, Connecticut, United States NorthShore University HealthSystem, Evanston, Illinois, United States Parkview Research Center, Fort Wayne, Indiana, United States Franciscan St. Francis Health, Indianapolis, Indiana, United States Ochsner Clinic Foundation, New Orleans, Louisiana, United States Lahey Hospital and Medical Center, Burlington, Massachusetts, United States Henry Ford Hospital Detroit, Detroit, Michigan, United States Allina Hospital Network, Minneapolis, Minnesota, United States State University of New York Hospital, Syracuse, New York, United States East Carolina University, Greenville, North Carolina, United States |
| 2164 | Completed | A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness | COVID-19 | Drug: LY3819253 Drug: LY3832479 Drug: LY3853113 Drug: Placebo |
Phase 3 | Eli Lilly and Company, AbCellera Biologics Inc., Shanghai Junshi Bioscience Co., Ltd. | INDUSTRY | 3307 | All | 0 Years | Clinnova Research - Redondo Beach, Redondo Beach, California, United States Bio-Medical Research, LLC, Miami, Florida, United States Rophe Adult and Pediatric Medicine, Union City, Georgia, United States Massachusetts General Hospital, Boston, Massachusetts, United States U of MA Mem Med Ctr, Worcester, Massachusetts, United States Great Lakes Research Group, Inc., Bay City, Michigan, United States Childrens Hospital of Michigan, Detroit, Michigan, United States Sky Clinical Prime and Health Wellness Clinic, Fayette, Mississippi, United States Sky Clin Resch - Quinn HC, Ridgeland, Mississippi, United States Monroe Biomed Research, Monroe, North Carolina, United States B S & W Med Center, Dallas, Texas, United States Sun Research Institute, San Antonio, Texas, United States |
| 2163 | Completed | A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff | SARS-CoV2 | Drug: Bamlanivimab Drug: Placebo Drug: Etesevimab |
Phase 3 | Eli Lilly and Company, National Institute of Allergy and Infectious Diseases (NIAID), AbCellera Biologics Inc., Shanghai Junshi Bioscience Co., Ltd. | INDUSTRY | 1180 | All | 18 Years | Unv of AL Sch of Med Div of Infectious Diseases, Birmingham, Alabama, United States Care Access Research, Phoenix, Arizona, United States Allergy and Asthma Clin of NW Ark, Bentonville, Arkansas, United States Care Access Research LLC, Huntington Beach, California, United States Alta Bates SMC, Oakland, California, United States University of Colorado-Anschultz Medical Campus, Aurora, Colorado, United States NIAID, Miami, Florida, United States NIAID, Decatur, Georgia, United States Belmont Village Lincoln Park, Lincoln Park, Illinois, United States Family Medicine, Indianapolis, Indiana, United States University of Louisville, Louisville, Kentucky, United States Care Access Rch Lake Charles, Lake Charles, Louisiana, United States Tulane University School of Medicine, New Orleans, Louisiana, United States NIAID - National Institute of Allergy & Infectious Diseases, Bethesda, Maryland, United States Care Access, Boston, Massachusetts, United States St. Paul IDA-CARe, Saint Paul, Minnesota, United States Care Access, Jackson, Mississippi, United States University of Mississippi Medical Center, Jackson, Mississippi, United States Children's Hospital & Medical Center, Omaha, Nebraska, United States Care Access Research - Bronx, Bronx, New York, United States NIAD, Chapel Hill, North Carolina, United States Valley Medical Primary Care, Centerville, Ohio, United States Univ of Cin College of Med, Cincinnati, Ohio, United States OSU Med Intl Med Houston Ctr, Tulsa, Oklahoma, United States Donahoe Manor, Bedford, Pennsylvania, United States Belmont Village, West Univ, Houston, Texas, United States Burke Internal Medicine and Research, Burke, Virginia, United States |
| 2162 | Completed | A Study of LY3819253 (LY-CoV555) in Participants Hospitalized for COVID-19 | COVID-19 | Drug: LY3819253 Drug: Placebo |
Phase 1 | Eli Lilly and Company, AbCellera Biologics Inc. | INDUSTRY | 26 | All | 18 Years ~ 75 Years | Cedars Sinai Medical Center, Los Angeles, California, United States Veterans Affairs Medical Center San Diego, San Diego, California, United States Emory University, Atlanta, Georgia, United States Massachusetts General Hospital, Boston, Massachusetts, United States University of Massachusetts Medical Center, Worcester, Massachusetts, United States University of Michigan, Ann Arbor, Michigan, United States Quality Clinical Research, Inc., Omaha, Nebraska, United States Alexandria Center for Life - NYC/ NYCEDC, New York, New York, United States University of North Carolina, Chapel Hill, North Carolina, United States Unified Research Enterprise Brody School of Medicine at ECU, Greenville, North Carolina, United States Temple Univ School of Med, Philadelphia, Pennsylvania, United States |
